SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (153)11/6/2002 6:47:47 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 684
 
>> Are you referring to my low number of posts over the last year or so? <<

No, just that it would have been nice to know about the transition of the B. Ingelheim drug to phase II.

I've been pointing to Charles Rice on the VPHM SAB for ages, and to the VPHM/Rice collaboration with BVDV. I think that it's a mistake to leave IRES out of your calculations re. the post-50406 targets.

One can't find two HCV-naive chimps these days? i haven't tried for 18 years.



To: Hank who wrote (153)12/8/2002 1:22:48 PM
From: AuBug  Read Replies (1) | Respond to of 684
 
I also like GCOR as well as DVSA which appears to have a broader range of techniques and product possibilities.

I dispute your claim regarding ABGX as Phage Display is a cheaper superior technology for developing human mAbs than using animals. I'd take a peek at DYAX.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News